Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms

Abstract Myeloproliferative neoplasms (MPNs) encompass a diverse group of hematologic disorders driven by mutations in JAK2, CALR, or MPL. The prevailing working model explaining how these driver mutations induce different disease phenotypes is based on the decisive influence of the cellular microen...

Full description

Bibliographic Details
Main Authors:	Kristin Holl, Nicolas Chatain, Susanne Krapp, Julian Baumeister, Tiago Maié, Sarah Schmitz, Anja Scheufen, Nathalie Brock, Steffen Koschmieder, Daniel Moreno-Andrés
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-02-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-024-53240-8

Similar Items

P988: MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS
by: Kristin Holl, et al.
Published: (2023-08-01)

Inflammation and anti-inflammatory approaches in myeloproliferative neoplasm
by: Steffen Koschmieder, et al.
Published: (2018-06-01)

Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms
by: Max Bermes, et al.
Published: (2023-12-01)

Mutant Calreticulin in the Myeloproliferative Neoplasms
by: Daniel Prins, et al.
Published: (2020-02-01)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
by: Julian Baumeister, et al.
Published: (2021-12-01)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
by: Kathrin Olschok, et al.
Published: (2023-10-01)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
by: Kathrin Olschok, et al.
Published: (2023-08-01)

Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms
by: Nicolas Chatain, et al.
Published: (2020-08-01)

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
by: Pecquet, C, et al.
Published: (2022)

The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia
by: Jingyi Wang, et al.
Published: (2016-08-01)

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms
by: Panhong Gou, et al.
Published: (2024-01-01)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
by: İpek Yonal Hindilerden, et al.
Published: (2023-08-01)

Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance
by: Saeid Shahrabi, et al.
Published: (2018-10-01)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
by: Sophie Allain-Maillet, et al.
Published: (2020-08-01)

The frequency of calreticulin and mpl gene mutations in bcr-abl and jak2 unmutated chronic myeloproliferative neoplasms and its effect on the outcome
by: T. Tiryaki, et al.
Published: (2020-10-01)

The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms
by: Steffen Koschmieder
Published: (2021-06-01)

P1046: SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
by: W. Novak, et al.
Published: (2022-06-01)

The JAK2V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
by: Lai Yee Orbell, et al.
Published: (2023-11-01)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
by: Fani Kalala, et al.
Published: (2012-06-01)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
by: Alexandre Guy, et al.
Published: (2020-06-01)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
by: Shirin Ferdowsi, et al.
Published: (2016-04-01)

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
by: Bench, A, et al.
Published: (2013)

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations
by: Bench, A, et al.
Published: (2013)

Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report
by: A, Alia Suzana, et al.
Published: (2023)

PB2193: JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS
by: Xuefei MA, et al.
Published: (2023-08-01)

Coexistence of JAK2V617F and CALR mutation in Tunisian cohort with Philadelphia-negative chronic myeloproliferative neoplasms
by: Hejer Elmahmoudi, et al.
Published: (2023-01-01)

Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms
by: Panhong Gou, et al.
Published: (2022-01-01)

P1009: SKLB054, A NOVEL JAK2 INHIBITOR, POTENTLY TREATS MYELOPROLIFERATIVE NEOPLASM WITH JAK2V617F MUTATION
by: Ailin Zhao, et al.
Published: (2023-08-01)

PB2040: INTERRELATION BETWEEN JAK2 V617F MUTATION AND THE INCIDENCE OF THROMBOTIC EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
by: D. Nikolova, et al.
Published: (2022-06-01)

Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms
by: Charly Courdy, et al.
Published: (2023-07-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-04-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-06-01)

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
by: Shivam Rai, et al.
Published: (2022-09-01)

P1001: MODULATION OF MUTANT CALRETICULIN-DRIVEN ONCOGENESIS IN MYELOPROLIFERATIVE NEOPLASMS BY CLASSICAL HLA GENES
by: Velizar Shivarov, et al.
Published: (2023-08-01)

Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
by: Greenfield, G, et al.
Published: (2020)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
by: Graeme Greenfield, et al.
Published: (2020-09-01)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
by: Michael Stephan Bader, et al.
Published: (2022-01-01)

SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm
by: Yue Yang, et al.
Published: (2023-11-01)

Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm
by: Mohammed Ferdous-Ur Rahman, et al.
Published: (2022-09-01)

Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
by: Megumi Funakoshi-Tago, et al.
Published: (2013-01-01)